Stocksigma LogoStocksigma Logo

Sudarshan Pharma Board Approves 9.50% Stake Acquisition in MedTherapy Biotechnology

Sudarshan Pharma Industries approved acquiring 24,23,675.64 equity shares (9.50% stake) of US-based MedTherapy Biotechnology Inc

Sudarshan Pharma Board Approves 9.50% Stake Acquisition in MedTherapy Biotechnology

Sudarshan Pharma Industries Ltd 路 Others (Uncategorized) 路 06 Sept 2026, 1:04 am

Sudarshan Pharma Board Approves 9.50% Stake Acquisition in MedTherapy Biotechnology Sudarshan Pharma Industries approved acquiring 24,23,675.64 equity shares (9.50% stake) of US-based MedTherapy Biotechnology Inc. via an all-cash transaction in USD, expected to close by 31st Mar'27. Additionally, promoters Hemal Mehta and Sachin Mehta will acquire 1.50% each (3,82,685.63 shares each). MedTherapy Biotech is a Boston-based CAR-T cell CDMO with manufacturing in New Delhi and R&D in Boston. The acquisition enables Sudarshan Pharma to establish a US footprint, access distribution networks, and broaden into cell and gene therapy offerings.

Original exchange filing (PDF)

More announcements from Sudarshan Pharma Industries Ltd

All Sudarshan Pharma Industries Ltd announcements